March 9, 2016 — One of Largest Financings Ever for a Private Scandinavian Biotech Company Participation by Top-Tier International Investors Funds to Support Next Stage of Clinical Development, including Phase II Trial in Ovarian Cancer, for APR-246, First-in-Class Anticancer Compound Reactivating